Navigation Links
Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers

TITUSVILLE, N.J., May 27 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., today announced the launch of the HIV Case Manager Portal (the Portal), a free, easy-to-use online resource at designed to help HIV/AIDS front-line service providers meet their daily client education and professional needs. The Portal was unveiled today in Denver, CO at the 22nd National Conference on Social Work and HIV/AIDS, the premier conference for service providers working with people living with HIV in the U.S.

Case managers, treatment educators, adherence specialists and other front-line service providers play a vital role in linking people living with HIV to the treatment and resources they need to successfully access and stay in care. These service providers often function as their clients' primary source for understanding and information on HIV disease, treatment and available supportive services. However, these front-line service providers often face barriers to delivering the best possible care to their clients.

"The everyday work of today's HIV service providers can be quite challenging," said Adele Webb, Ph.D., RN, executive director of the Association of Nurses in AIDS Care, a collaborator on the Portal. "Case managers, social workers and nurses must address an incredible range of needs to help their diverse client base navigate a complicated HIV care system. Services like the HIV Case Manager Portal are a welcome resource to streamline this process and will save time that these providers can dedicate to their clients."

The Portal is the result of a year-long effort by Tibotec Therapeutics to identify and address some of the major obstacles to successful case management. Consultations and focus groups with service providers from a wide spectrum of HIV/AIDS organizations revealed that they frequently lack easily accessible and appropriate tools and resources needed to effectively serve their clients. A source for up-to-date, relevant information on HIV disease and other services, the Portal aims to help address these unmet needs by providing front-line service providers with a centralized resource to help them educate their clients and further their own professional development.

The Portal includes several important, useful tools to facilitate conversations about HIV disease, treatment and care between service providers and their clients. Service providers can access an expansive and growing content library of easy-to-read fact sheets, available in both English and Spanish, to share with their clients that address a wide array of topics on HIV disease, treatment, prevention and healthy living. Through the Portal's unique "Brochure Builder" feature, these fact sheets can be combined and customized for clients based on their individual needs and characteristics.

The Portal also contains helpful resources to support the everyday professional and educational needs of front-line service providers. To enhance their professional development, the Portal's "CEU Credit Tracker" helps users record their completed continuing education credits and identify new educational opportunities. For service providers new to the HIV/AIDS field, the Portal offers an introductory "HIV/AIDS 101 Training Module" designed to provide a basic overview of HIV disease, treatment and care. Users can opt-in to locate other case managers and service providers across the U.S. to better serve a mobile client population and ease clients' transitions to new locations and care providers. Quick links to social services and treatment assistance resources help service providers address the specific needs of HIV/AIDS patients with limited means. Additionally, the Portal offers links to more than 200 national, state and city HIV/AIDS organizations and resources to simplify online navigation.

"We at Tibotec Therapeutics are very pleased to support the important work of case managers and other front-line service providers through resources like the HIV Case Manager Portal," said Glenn Mattes, President of Tibotec Therapeutics. "We hope the Portal serves as an innovative first step in the development of a forum for service providers from a wide spectrum of locations, backgrounds and organizations to gather and access information to help improve the health of their clients."

Pilot tested at the United States Conference on AIDS (USCA), HIV service providers shared valuable feedback on the overall appearance, content and utility of the Portal and its resources. In a survey of 96 service providers, 83 percent said they would be very likely or likely to use the site, 75 percent said the content was very good or excellent, and 81 percent said they were very likely or likely to share its content with their clients. To ensure that this effort continues to grow and evolve to meet the diverse and ever-changing needs of the front-line service provider community, Tibotec Therapeutics has collaborated with the Association of Nurses in AIDS Care (ANAC), HealthHIV and the National Alliance of State & Territorial AIDS Directors (NASTAD).

To register and learn more about the HIV Case Manager Portal and its resources, please visit

About Tibotec Therapeutics

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., headquartered in Titusville, N.J., is dedicated to delivering innovative virology therapeutics that help health care professionals address serious unmet needs in people living with HIV. For more information, visit

SOURCE Tibotec Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
6. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
7. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
8. Logical Therapeutics Secures $16.9M Series C Financing Round
9. Sorrento Therapeutics Awarded NIH Grant for MRSA Program
10. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
11. New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... NEW YORK , November 25, 2015 ... global market of self-monitoring blood glucose devices was valued ... to grow with a CAGR of 5.7% during 2015 ... increasing geriatric population and increasing prevalence of diabetes. In ... about diabetes care is also contributing to the growth ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Complex (TSC), as well as raising public awareness of the disorder while helping ... a third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted ... to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ ... of time the doctor uses other traditional cutting tools, such as the scalpel and ...
Breaking Medicine News(10 mins):